Literature DB >> 12691792

Age-related differences in the side effect profile of citalopram.

Yoram Barak1, Marnina Swartz, Daniel Levy, Ronit Weizman.   

Abstract

The authors evaluated the autonomic and cardiovascular side effects of citalopram with particular emphasis on their relation to the age of treated patients. The data that formed the basis for the U.S. Food and Drug Administration approval of citalopram were provided by Lundbeck (Copenhagen, Denmark). This database included placebo-controlled short- and long-term studies in major depressed patients. The list of side effects comprised all "heart rate and rhythm disorders" as well as "autonomic nervous system disorders" that had been reported by at least 5% more than that reported for the placebo group of subjects. The database encompassed 1344 subjects treated with citalopram (20-60 mg/day) for a period of no less than 6 weeks. Statistically significant age-related distribution was found for five side effects: bradycardia, nausea, diarrhea, sweating and headache. Bradycardia was more prevalent in elderly (>65 years) patients as compared to the younger population (2.4% vs. 0.2%, P<.05), whereas gastrointestinal side effects, sweating and headache were less prevalent in the elderly. The age-related differences in the side effect profile may be attributable to altered sensitivity of the serotonergic system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12691792     DOI: 10.1016/S0278-5846(03)00041-1

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  6 in total

1.  Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.

Authors:  Yuyan Jin; Bruce G Pollock; Ellen Frank; Giovanni B Cassano; Paola Rucci; Daniel J Müller; James L Kennedy; Rocco Nicola Forgione; Margaret Kirshner; Gail Kepple; Andrea Fagiolini; David J Kupfer; Robert R Bies
Journal:  J Clin Pharmacol       Date:  2009-10-19       Impact factor: 3.126

Review 2.  Antidepressants and falls in the elderly.

Authors:  Adam Darowski; Sally-Ann C F Chambers; David J Chambers
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 3.  Serotonergic receptor gene polymorphism and response to selective serotonin reuptake inhibitors in ethnic Malay patients with first episode of major depressive disorder.

Authors:  Ibrahim Mohammed Badamasi; Munn Sann Lye; Normala Ibrahim; Nurul Asyikin Abdul Razaq; King Hwa Ling; Johnson Stanslas
Journal:  Pharmacogenomics J       Date:  2021-03-17       Impact factor: 3.550

4.  Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly.

Authors:  Muh Akbar Bahar; Yuanyuan Wang; Jens H J Bos; Bob Wilffert; Eelko Hak
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-03-24       Impact factor: 2.890

5.  Population pharmacokinetics model for escitalopram in Chinese psychiatric patients: effect of CYP2C19 and age.

Authors:  Shujing Liu; Tao Xiao; Shanqing Huang; Xiaolin Li; Wan Kong; Ye Yang; Zi Zhang; Xiaojia Ni; Haoyang Lu; Ming Zhang; Dewei Shang; Yuguan Wen
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

6.  The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine.

Authors:  Muh Akbar Bahar; Jasper Kamp; Sander D Borgsteede; Eelko Hak; Bob Wilffert
Journal:  Br J Clin Pharmacol       Date:  2018-09-24       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.